| Literature DB >> 31797963 |
Héloïse Proquin1, Marloes C M Jonkhout2, Marlon J Jetten3, Henk van Loveren1, Theo M de Kok1, Jacob J Briedé4.
Abstract
The food additive titanium dioxide (TiO2), or E171, is a white food colorant. Recent studies showed after E171 ingestion a significantly increased number of colorectal tumours in a colorectal cancer mouse model as well as inflammatory responses and dysregulation of the immune system in the intestine of rats. In the mouse colon, E171 induced gene expression changes related to oxidative stress, impairment of the immune system, activation of signalling and cancer-related processes. E171 comprises nanoparticles (NPs) and microparticles (MPs). Previous in vitro studies showed that E171, NPs and MPs induced oxidative stress responses, DNA damage and micronuclei formation. This study aimed to investigate the relative contribution of the NPs and MPs to effects of E171 at the transcriptome level in undifferentiated Caco-2 cells by genome wide microarray analysis. The results showed that E171, NPs, and MPs induce gene expression changes related to signalling, inflammation, immune system, transport and cancer. At the pathway level, metabolism of proteins with the insulin processing pathway and haemostasis were specific to E171 exposure. The gene expression changes associated with the immune system and inflammation induced by E171, MPs, and NPs suggest the creation of a favourable environment for colon cancer development.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31797963 PMCID: PMC6893026 DOI: 10.1038/s41598-019-54675-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
DEG per time point after Caco-2 cells exposure to TiO2 NPs.
| FC ≥ 1.2 | FC ≥ 1.5 | FC ≥ 1.8 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 2 h | 4 h | 24 h | 2 h | 4 h | 24 h | 2 h | 4 h | 24 h | |
| |FC| | 3827 | 5220 | 3916 | 806 | 797 | 623 | 253 | 155 | 248 |
| Upregulated | 2004 | 2051 | 1978 | 595 | 503 | 234 | 214 | 63 | 169 |
| Downregulated | 1823 | 3169 | 1938 | 211 | 294 | 389 | 39 | 92 | 79 |
| p.val < 0.05 | 532 | 1991 | 470 | 532 | 470 | 1991 | 532 | 1991 | 470 |
| adj.p.val < 0.05 | 0 | 3 | 0 | 0 | 0 | 3 | 0 | 3 | 0 |
| 434 | 1532 | 432 | 121 | 88 | 129 | ||||
| |FC| and adj.p.val | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
A LIMMA test was used in R with a fold change (FC) of > = 1.2, 1.5 or 1.8 and a p-value < 0.05. DEG used for the analysis are shown in bold. |FC| = Fold Change, p.val = p-value, adj.p.val = adjusted p-value.
Figure 1Overlap of DEG over time after exposure to TiO2 NPs for 2, 4 or 24 hours. Venn diagrams representing the overlap of (A) all DEG, (B) upregulated DEG and (C) downregulated DEG.
Pathway over-representation analysis (ORA) of the DEG.
| Time of exposure | Biological function | Name pathway | p-value |
|---|---|---|---|
| 2 h | Signal Transduction | Olfactory receptor activity | 3.03E-09 |
| Olfactory transduction | 4.73E-09 | ||
| Olfactory Signalling Pathway | 8.72E-09 | ||
| GPCR downstream Signalling | 6.47E-07 | ||
| Signalling by GPCR | 1.60E-06 | ||
| GPCRs, Class A Rhodopsin-like | 0.00518 | ||
| Signal Transduction | 0.0125 | ||
| Immune system | 0.0113 | ||
| Dectin-2 family | 0.0125 | ||
| Metabolism | Vitamin A and Carotenoid Metabolism | 0.0297 | |
| Retinol metabolism | 0.0468 | ||
| Transport | Cation-coupled Chloride cotransporters | 0.0125 | |
| 4 h | Signal Transduction | Olfactory Signalling Pathway | 1.57E-05 |
| Olfactory receptor activity | 9.53E-05 | ||
| Olfactory transduction | 9.53E-05 | ||
| GPCR downstream Signalling | 0.000714 | ||
| Signalling by GPCR | 0.000807 | ||
| GPCR Signalling-G alpha i | 0.0223 | ||
| GPCR Signalling-pertussis toxin | 0.0223 | ||
| VEGF binds to VEGFR leading to receptor dimerization | 0.0223 | ||
| VEGF ligand-receptor interactions | 0.0223 | ||
| GPCR Signalling-cholera toxin | 0.0234 | ||
| GPCR Signalling-G alpha s Epac and ERK | 0.0234 | ||
| GPCR Signalling-G alpha q | 0.0234 | ||
| VEGF and VEGFR Signalling network | 0.0234 | ||
| Signal Transduction | 0.0234 | ||
| GPCR Signalling-G alpha s PKA and ERK | 0.0234 | ||
| Metabolism | Serotonin and melatonin biosynthesis | 0.0127 | |
| Bile acid and bile salt metabolism | 0.029 | ||
| Peptide hormone metabolism | 0.029 | ||
| Synthesis of bile acids and bile salts via 24-hydroxycholesterol | 0.029 | ||
| Biogenic Amine Synthesis | 0.037 | ||
| Metabolism of Angiotensinogen to Angiotensins | 0.0389 | ||
| Primary bile acid biosynthesis | 0.0407 | ||
| Amine-derived hormones | 0.044 | ||
| Transport | Ligand-gated ion channel transport | 0.00701 | |
| Transport of organic anions | 0.0234 | ||
| Transmembrane transport of small molecules | 0.029 | ||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | 0.0389 | ||
| Neuronal system | Serotonin and anxiety | 0.029 | |
| Serotonergic synapse | 0.0407 | ||
| Neuroactive ligand-receptor interaction | 0.0446 | ||
| 24 h | Signal Transduction | Gastrin-CREB Signal Transduction pathway via PKC and MAPK | 0.108 |
| Peptide ligand-binding receptors | 0.108 | ||
| Class A/1 (Rhodopsin-like receptors) | 0.108 | ||
| G alpha (i) Signal Transduction events | 0.128 | ||
| Immune system | Negative regulation of MAPK pathway | 0.131 | |
| Metabolism | Glucocorticoid Receptor Pathway | 0.00221 | |
| Glycine, serine, alanine and threonine metabolism | 0.0207 | ||
| Creatine metabolism | 0.108 | ||
| Prostaglandin Synthesis and Regulation | 0.108 | ||
| Metabolism of polyamines | 0.128 | ||
| Transport | Bile salt and organic anion SLC transporters | 0.128 | |
| Neuronal system | TarBasePathway | 0.128 | |
| HCN channels | 0.03 | ||
| Cancer | Photodynamic therapy-induced HIF-1 survival Signalling | 0.128 | |
| Gene expression (Transcription) | TP53 Regulates Transcription of Cell Cycle Genes | 0.128 | |
| Developmental biology | Endoderm Differentiation | 0.128 | |
| Developmental Biology | 0.108 | ||
| Haemostasis | Hemostasis | 0.0382 |
Pathways related to the DEG after ORA with ConsensusPathDB. The pathways were grouped per time points and per biological function.
Figure 2Overlap of GO terms and their biological processes over time. Venn diagram representing (A): the number of GO terms in common between 2, 4, and 24 h exposure to TiO2 NPs, and (B): the associated biological processes to the GO terms in common between 2, 4, and 24 h exposure to TiO2 NPs.
DEG after exposure of Caco-2 cells to different TiO2 particles for 24 h.
| NPs | MPs | E171 | |
|---|---|---|---|
| |FC| > = 1.5 | 415 | 365 | 1040 |
| Upregulated | 148 | 136 | 63 |
| Downregulated | 267 | 229 | 977 |
| p.val < 0.05 | 664 | 459 | 1198 |
| adj.p.val < 0.05 | 0 | 0 | 0 |
| |FC| and adj.p.val | 0 | 0 | 0 |
A LIMMA test was used in R with a fold change (FC) of >=1.5 and a p-value < 0.05 after in vitro exposure to E171, MPs, and NPs of TiO2. The number of DEG used for further analysis is shown in bold. |FC| = Fold Change, p.val = p-value, adj.p.val = adjusted p-value.
Figure 3Unique and common DEG between E171 and the different size fractions of TiO2. Venn diagram showing the overlap of DEG after exposure of undifferentiated Caco-2 cells to E171, MPs, and NPs for 24 h.
Pathways associated with the DEG after NPs, MPs and E171 exposure.
| Time of exposure | Biological function | Name pathway | p-value |
|---|---|---|---|
| E171 | Signal Transduction | GPCR downstream signalling | 1.09E-08 |
| Signalling by GPCR | 3.75E-07 | ||
| Olfactory Signalling Pathway | 2.05E-06 | ||
| Olfactory transduction - Homo sapiens (human) | 3.36E-05 | ||
| Olfactory receptor activity | 6.69E-05 | ||
| GPCR ligand binding | 0.000236 | ||
| Signal Transduction | 0.000461 | ||
| G alpha (q) signalling events | 0.00222 | ||
| Bone Morphogenic Protein (BMP) Signalling and Regulation | 0.00845 | ||
| Transport of small molecules | Zinc efflux and compartmentalization by the SLC30 family | 0.00406 | |
| Neuronal system | Dopaminergic Neurogenesis | 0.0004 | |
| Developmental Biology | Interaction between L1 and Ankyrins | 0.0041 | |
| Haemostasis | Endothelins | 0.00989 | |
| Metabolism of proteins | Insulin processing | 0.00406 | |
| MPs | Signal Transduction | Olfactory Signalling Pathway | 0.0579 |
| Olfactory transduction - Homo sapiens (human) | 0.0579 | ||
| Developmental Biology | CDO in myogenesis | 0.0654 | |
| Myogenesis | 0.0654 | ||
| Netrin-1 signalling | 0.0775 | ||
| NPs | Metabolism | Glycine, serine, alanine and threonine metabolism | 0.000543 |
| Creatine metabolism | 0.000789 | ||
| Urea cycle and metabolism of amino groups | 0.00514 | ||
| Glucocorticoid Receptor Pathway | 0.00541 | ||
| Prostaglandin Synthesis and Regulation | 0.00861 | ||
| Neuronal system | HCN channels | 8.60E-05 | |
| TarBasePathway | 0.00126 | ||
| Potassium Channels | 0.00689 | ||
| Transport of small molecules | Amino acid transport across the plasma membrane | 0.00926 |
ORA analysis performed with CPDB on all the DEG after NPs, MPs and E171 exposure in vitro for 24 h.
Figure 4Overlap of the biological processes between the different sizes of TiO2. Venn diagram showing after exposure of undifferentiated Caco-2 cells to E171, MPs, and NPs for 24 h (A): the overlap of biological processes after ORA, (B): the overlap of the biological processes related to the GO terms.